U.S. markets close in 4 hours 43 minutes
  • S&P 500

    3,966.45
    +2.94 (+0.07%)
     
  • Dow 30

    33,751.29
    -30.19 (-0.09%)
     
  • Nasdaq

    11,107.36
    +25.35 (+0.23%)
     
  • Russell 2000

    1,813.54
    -4.75 (-0.26%)
     
  • Crude Oil

    72.65
    +1.19 (+1.67%)
     
  • Gold

    1,809.60
    +8.10 (+0.45%)
     
  • Silver

    23.61
    +0.37 (+1.59%)
     
  • EUR/USD

    1.0541
    -0.0019 (-0.18%)
     
  • 10-Yr Bond

    3.5440
    +0.0530 (+1.52%)
     
  • GBP/USD

    1.2292
    +0.0054 (+0.44%)
     
  • USD/JPY

    136.5040
    -0.1260 (-0.09%)
     
  • BTC-USD

    17,183.47
    +259.89 (+1.54%)
     
  • CMC Crypto 200

    404.91
    -1.34 (-0.33%)
     
  • FTSE 100

    7,477.77
    +5.60 (+0.07%)
     
  • Nikkei 225

    27,901.01
    +326.58 (+1.18%)
     

Adaptimmune's Cancer Candidate Shows 44% Response Rate In Pretreated Ovarian, Urothelial, Head & Neck Cancers

  • Adaptimmune Therapeutics plc (NASDAQ: ADAPannounces data from its signal-finding Phase 1 SURPASS trial of ADP-A2M4CD8 in solid tumor settings. The data will be presented at the European Society for Medical Oncology (ESMO) 2022 Congress.

  • The Phase 1 SURPASS trial is ongoing, and the overall response rate for the 43 evaluable people is 33% (including confirmatory scans for two people with unconfirmed partial responses).

  • Most people experienced meaningful antitumor activity with a disease control rate of 81%. The median duration of response was 12 weeks.

  • For the subset of 25 people with ovarian, urothelial, and head & neck cancers, the response rate is 44%.

  • In ovarian cancer patients, most people had reductions in target lesions and an 86% disease control rate, and 5 (36%) had confirmed clinical responses, including one complete response.

  • The company plans to start Phase 2 SURPASS-3 trial in late 2022/early 2023 in ovarian cancer.

  • In urothelial cancer, 6 out of 7 people had reductions in target lesions, and three had confirmed responses. In addition, one unconfirmed response was received after the data cut-off.

  • In head & neck cancer, three confirmed responses out of 4 people were observed.

  • In gastroesophageal cancers, one confirmed and one unconfirmed response was subsequently confirmed after the data cut-off. There is clear antitumor activity in these cancers with an encouraging disease control rate (10 out of 13 people) in this heavily pre-treated advanced population.

  • Price Action: ADAP shares are down 1.47% at $2.01 on the last check Friday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.